Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
about
Discovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive SystemsPharmacogenetics in drug regulation: promise, potential and pitfalls.Polymorphic hydroxylation of perhexiline in vitro.Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady stateClinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemiaMechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Personalized medicine: is it a pharmacogenetic mirage?Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexilineCan pharmacogenetics help rescue drugs withdrawn from the market?Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.Pleiotropic mechanisms of action of perhexiline in heart failure.Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and TherapeuticsStereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.The validation of an LC-MS/MS assay for perhexiline and major hydroxy metabolites, and its application to therapeutic monitoring in patient plasma.CYP450 genotype and pharmacogenetic association studies: a critical appraisal
P2860
Q28553478-A9CBF863-D698-4CC2-A285-B4F200EDC5FFQ35038052-D54B931D-CE98-4ABF-869A-F69A14DA7BBDQ35825349-774EC66F-C153-4D4B-9CE3-A1A4C1803854Q35825990-18CB4519-8FCC-4FA6-9EB5-F8A271E3F7E9Q35826004-0EA63469-C9DF-4E64-9D76-8777B75C6790Q35826495-12C2271A-74C6-4927-B7AC-F624E65D8ADEQ35827498-D239F3DD-9B70-42F8-9ABD-2BBF30C91C85Q36040772-4346D1A0-DF1F-4B5D-8C38-3142B5BE3232Q36336007-C055D86B-DE00-480C-8D63-74E0A1DA38DEQ36535908-CE89779B-FFC5-44E5-9770-60C989FDF240Q36596713-BE5D5FE6-38BE-4AAE-97B8-EA74CC7489BBQ38815503-8F6F1394-2B66-4CE7-BE1D-0C6EE2A6EC78Q38907804-6A192F04-47A7-4FD5-B703-C117EB48B3EDQ39051498-2C827EDA-F757-4D70-8F21-DDA3CEFCC501Q42361532-67E6F639-FC87-421B-8D47-45D91BAD85E9Q53670883-76209EA2-8B26-4C53-9425-80CDF90F21D4Q53811688-6DA5AC1E-2048-43F4-9217-A4F8B3BDBA02Q57585515-8CA3B96C-7AA1-47AB-95DD-BD8F0DD60635
P2860
Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pharmacokinetics of the antian ...... c ratio and steady-state dose.
@en
Pharmacokinetics of the antian ...... c ratio and steady-state dose.
@nl
type
label
Pharmacokinetics of the antian ...... c ratio and steady-state dose.
@en
Pharmacokinetics of the antian ...... c ratio and steady-state dose.
@nl
prefLabel
Pharmacokinetics of the antian ...... c ratio and steady-state dose.
@en
Pharmacokinetics of the antian ...... c ratio and steady-state dose.
@nl
P2093
P2860
P1476
Pharmacokinetics of the antian ...... c ratio and steady-state dose.
@en
P2093
Benedetta C Sallustio
Ian S Westley
Raymond G Morris
P2860
P304
P356
10.1046/J.1365-2125.2002.01618.X
P407
P577
2002-08-01T00:00:00Z